Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$4,032 | $52,154 | -$33,361 | $57,138 |
| Dep. & Amort. | $35,239 | $36,521 | $51,370 | $50,946 |
| Deferred Tax | -$15,800 | $11,696 | $20,723 | -$8,618 |
| Stock-Based Comp. | $41,089 | $25,743 | $60,285 | $38,783 |
| Change in WC | $19,356 | -$34,402 | $65,677 | -$52,164 |
| Other Non-Cash | $21,195 | -$42,135 | -$26,844 | -$7,287 |
| Operating Cash Flow | $97,047 | $49,577 | $137,850 | $78,798 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,821 | -$3,521 | -$17,923 | -$8,761 |
| Net Acquisitions | -$172,190 | -$25,654 | -$750 | $494 |
| Inv. Purchases | -$226,384 | -$126,764 | -$51,226 | -$181,325 |
| Inv. Sales/Matur. | $269,621 | $194,167 | $234,391 | $221,335 |
| Other Inv. Act. | -$12,890 | -$49,910 | -$868 | -$1,220 |
| Investing Cash Flow | -$143,664 | -$11,682 | $163,624 | $30,523 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$25 | -$76,899 | -$261,003 | -$146,010 |
| Stock Issued | $37,140 | $0 | $0 | $33,763 |
| Stock Repurch. | $0 | $0 | -$8,236 | -$18,446 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $60,026 | $16,952 | -$6,751 | -$7,068 |
| Financing Cash Flow | $97,141 | -$59,947 | -$275,990 | -$137,761 |
| Forex Effect | -$1,171 | $0 | $0 | $0 |
| Net Chg. in Cash | $49,353 | -$22,052 | $25,484 | -$28,440 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $22,954 | $45,006 | $19,522 | $47,962 |
| End Cash | $72,307 | $22,954 | $45,006 | $19,522 |
| Free Cash Flow | $77,407 | -$4,272 | $119,927 | $70,037 |